{
  "guideline": {
    "id": "PA166104890",
    "name": "Annotation of FDA Label for ivacaftor and CFTR",
    "source": "FDA",
    "version": 41,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104890",
    "relatedChemicals": [
      {
        "id": "PA165950341",
        "name": "ivacaftor",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA109",
        "name": "cystic fibrosis transmembrane conductance regulator",
        "symbol": "CFTR"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166311821",
      "name": "Recommendation Annotation PA166311821",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA165950341",
          "name": "ivacaftor",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216000,
        "html": "<p>&quot;KALYDECO [ivacaftor] is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 12 months or older who have one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CFTR": "ivacaftor responsive in CF patients"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Kalydeco (ivacaftor), NDA203188, Vertex Pharmaceuticals Incorporated",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203188"
    }
  ],
  "version": "2024-02-29-20-19"
}